Literature DB >> 18434304

Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high density lipoprotein.

Alison A Gardner1, Ethan C Reichert, Matthew K Topham, Diana M Stafforini.   

Abstract

The plasma form of platelet-activating factor (PAF) acetylhydrolase (PAF-AH), also known as lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) inactivates potent lipid messengers such as PAF and modified phospholipids generated in settings of oxidant stress. In humans, PAF-AH circulates in blood in fully active form and associates with high and low density lipoproteins (HDL and LDL). Several studies suggest that the location of PAF-AH affects both the catalytic efficiency and the function of the enzyme in vivo. The distribution of PAF-AH among lipoproteins varies widely among mammals. Here, we report that mouse and human PAF-AHs associate with human HDL particles of different density. We made use of this observation in the development of a binding assay to identify domains required for association of human PAF-AH with human HDL. Sequence comparisons among species combined with domain-swapping and site-directed mutagenesis studies led us to the identification of C-terminal residues necessary for the association of human PAF-AH with human HDL. Interestingly, the region identified is not conserved among PAF-AHs, suggesting that PAF-AH interacts with HDL particles in a manner that is unique to each species. These findings contribute to our understanding of the mechanisms responsible for association of human PAF-AH with HDL and may facilitate future studies aimed at precisely determining the function of PAF-AH in each lipoprotein particle.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18434304      PMCID: PMC2427361          DOI: 10.1074/jbc.M802394200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  62 in total

1.  Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up.

Authors:  Emmanouil S Brilakis; Joseph P McConnell; Ryan J Lennon; Ahmad A Elesber; Jeffrey G Meyer; Peter B Berger
Journal:  Eur Heart J       Date:  2004-11-29       Impact factor: 29.983

2.  Ratio of LDL- to HDL-associated platelet-activating factor acetylhydrolase may be a marker of inflammation in patients with paroxysmal atrial fibrillation.

Authors:  Keisuke Okamura; Shin-ichiro Miura; Bo Zhang; Yoshinari Uehara; Kunihiro Matsuo; Koichiro Kumagai; Keijiro Saku
Journal:  Circ J       Date:  2007-02       Impact factor: 2.993

3.  Molecular basis for susceptibility of plasma platelet-activating factor acetylhydrolase to oxidative inactivation.

Authors:  Amy N MacRitchie; Alison A Gardner; Stephen M Prescott; Diana M Stafforini
Journal:  FASEB J       Date:  2007-01-08       Impact factor: 5.191

Review 4.  Clinical aspects of plasma platelet-activating factor-acetylhydrolase.

Authors:  Ken Karasawa
Journal:  Biochim Biophys Acta       Date:  2006-09-01

5.  Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome.

Authors:  Evangelos Rizos; Afroditi P Tambaki; Irene Gazi; Alexandros D Tselepis; Moses Elisaf
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2005-03       Impact factor: 4.006

6.  Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis.

Authors:  Evagelos N Liberopoulos; Eleni Papavasiliou; George A Miltiadous; Marios Cariolou; Kostas C Siamopoulos; Alexandros D Tselepis; Moses S Elisaf
Journal:  Perit Dial Int       Date:  2004 Nov-Dec       Impact factor: 1.756

7.  Phospholipase action of platelet-activating factor acetylhydrolase, but not paraoxonase-1, on long fatty acyl chain phospholipid hydroperoxides.

Authors:  Tamas Kriska; Gopal K Marathe; Jacob C Schmidt; Thomas M McIntyre; Albert W Girotti
Journal:  J Biol Chem       Date:  2006-11-06       Impact factor: 5.157

8.  Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.

Authors:  Marc S Sabatine; David A Morrow; Michelle O'Donoghue; Kathleen A Jablonksi; Madeline Murguia Rice; Scott Solomon; Yves Rosenberg; Michael J Domanski; Judith Hsia
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-08-31       Impact factor: 8.311

Review 9.  Predicting the risk of cardiovascular disease: where does lipoprotein-associated phospholipase A(2) fit in?

Authors:  Natalie Khuseyinova; Wolfgang Koenig
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

10.  The association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients.

Authors:  Matthew A Allison; Julie O Denenberg; Jeanenne J Nelson; Loki Natarajan; Michael H Criqui
Journal:  J Vasc Surg       Date:  2007-07-30       Impact factor: 4.268

View more
  19 in total

Review 1.  Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

Authors:  Robert S Rosenson; Diana M Stafforini
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

2.  Dual roles of endogenous platelet-activating factor acetylhydrolase in a murine model of necrotizing enterocolitis.

Authors:  Jing Lu; Marissa Pierce; Andrew Franklin; Tamas Jilling; Diana M Stafforini; Michael Caplan
Journal:  Pediatr Res       Date:  2010-09       Impact factor: 3.756

3.  Determination of phospholipase activity of PAF acetylhydrolase.

Authors:  Diana M Stafforini; Thomas M McIntyre
Journal:  Free Radic Biol Med       Date:  2012-05-29       Impact factor: 7.376

4.  Circulating platelet-activating factor is primarily cleared by transport, not intravascular hydrolysis by lipoprotein-associated phospholipase A2/ PAF acetylhydrolase.

Authors:  Jinbo Liu; Rui Chen; Gopal K Marathe; Maria Febbraio; Weilin Zou; Thomas M McIntyre
Journal:  Circ Res       Date:  2010-12-23       Impact factor: 17.367

5.  Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development.

Authors:  Robert L Wilensky; Yi Shi; Emile R Mohler; Damir Hamamdzic; Mark E Burgert; Jun Li; Anthony Postle; Robert S Fenning; James G Bollinger; Bryan E Hoffman; Daniel J Pelchovitz; Jisheng Yang; Rosanna C Mirabile; Christine L Webb; LeFeng Zhang; Ping Zhang; Michael H Gelb; Max C Walker; Andrew Zalewski; Colin H Macphee
Journal:  Nat Med       Date:  2008-09-21       Impact factor: 53.440

Review 6.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

Review 7.  Lipoprotein-associated phospholipase A2: The story continues.

Authors:  Fubao Huang; Kai Wang; Jianhua Shen
Journal:  Med Res Rev       Date:  2019-05-29       Impact factor: 12.944

8.  Specificity of lipoprotein-associated phospholipase A(2) toward oxidized phosphatidylserines: liquid chromatography-electrospray ionization mass spectrometry characterization of products and computer modeling of interactions.

Authors:  Vladimir A Tyurin; Naveena Yanamala; Yulia Y Tyurina; Judith Klein-Seetharaman; Colin H Macphee; Valerian E Kagan
Journal:  Biochemistry       Date:  2012-11-19       Impact factor: 3.162

9.  Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study.

Authors:  Sunil Suchindran; David Rivedal; John R Guyton; Tom Milledge; Xiaoyi Gao; Ashlee Benjamin; Jennifer Rowell; Geoffrey S Ginsburg; Jeanette J McCarthy
Journal:  PLoS Genet       Date:  2010-04-29       Impact factor: 5.917

10.  Crystal structure of human plasma platelet-activating factor acetylhydrolase: structural implication to lipoprotein binding and catalysis.

Authors:  Uttamkumar Samanta; Brian J Bahnson
Journal:  J Biol Chem       Date:  2008-09-10       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.